Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case series evaluated the use of oral bicalutamide with low-dose oral minoxidil in women with female pattern hair loss who didn't respond to minoxidil alone, finding that 96.6% showed improvement after six months without adverse effects.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

This compilation lists potential side effects, drug interactions, and trade names of various dermatological and antiretroviral medications, but it reports no original research findings.

This study suggests that combining the 5α-reductase inhibitor 4-MA with the antiandrogen Flutamide may improve prostate cancer therapy by additively inhibiting prostatic growth and androgen-sensitive functions in rats.

There is no abstract available for this article on the effects of percutaneous oestradiol implants on the skeletons of postmenopausal women, and thus no new findings are reported.

After the FDA's 2011 warning about a potential prostate cancer risk with 5-alpha reductase inhibitors, this study observed a significant decrease in their prescriptions, notably a 49% drop among men with benign prostatic hyperplasia, while primary care providers reduced prescriptions by 60%.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This article discusses the various skin side effects associated with targeted cancer therapies like tyrosine kinase inhibitors and EGF-R inhibitors but provides no new clinical findings.

Spironolactone can cause side effects like high potassium levels and breast enlargement, and patients need careful monitoring.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

In this study, docetaxel combined with prednisone significantly extended survival by about 2.5 months in men with hormone-resistant metastatic prostate cancer compared to mitoxantrone plus prednisone, despite the potential for severe adverse effects.

This study found that emodin from Polygonum multiflorum showed 5alpha-reductase inhibitory activity, which was more potent than alizarin but less potent than riboflavin.

This study uses cryo-electron microscopy to reveal how androgen receptor forms a non-obligate dimer to bind DNA, with implications for prostate cancer development.

This integrative review found that while hormone therapy, under proper medical supervision, can improve quality of life by treating conditions like muscle and bone mass loss, using these hormones without clinical need poses serious risks to neurological, cardiac, hepatic, renal, and reproductive health.

This study found that among 17 beta-(N-ureylene-N,N'-disubstituted)-4-azasteroids, those with an N'-phenyl moiety were the most effective inhibitors of human type I 5 alpha-reductase.

In this study, anti-androgenic therapy with finasteride for prostate disease was associated with reduced cardiac hypertrophy in heart failure patients, encouraging further investigation in larger cohorts.

This abstract reviews the use and effects of various antiandrogens, finding clinical benefits in treating hyperandrogenism in women and improvements in urinary symptoms or cancer management in men, but it reports no new clinical results.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

This review discusses advances in drug delivery systems to enhance oleanolic acid's bioavailability and therapeutic potential but reports no new clinical results.

This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.

In this study, researchers characterized a dehydroepiandrosterone hydroxylating enzyme system in hair follicles similar to the liver monooxygenase system, noting its inhibition by carbon monoxide and its dependence on NADPH.

This study reports that hedgehog pathway inhibitors, sonidegib and vismodegib, showed distinct adverse event patterns in real-world data, suggesting the need for further research to confirm these findings.

This study found that using elastic nano-liposomes to deliver palmitoylethanolamide improved its transdermal delivery and enhanced its skincare effects, with minimal cytotoxicity and no allergic reactions observed.

This review discusses the role of skeletal muscle in synthesizing bioactive androgens, highlighting that intramuscular androgens may influence muscle via intracrine action, but their precise function remains unclear.